SCHEMBL25157142

SCHEMBL25157142

CC(C)CNc1ncc2c(-c3ccc4ncncc4c3)c[nH]c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 2/20 0.52
▸ DYRK1A Q13627 10/20 0.41
▸ CLK3 P49761 3/20 0.41
▸ CLK2 P49760 2/20 0.41
▸ BRD4 O60885 2/20 0.40
▸ GSK3B P49841 3/20 0.40
▸ MAP4K4 O95819 2/20 0.38
▸ PIK3CD O00329 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ CLK1 P49759 2/20 0.37
▸ CLK4 Q9HAZ1 2/20 0.37
▸ EGFR P00533 1/20 0.36
▸ LATS1 O95835 1/20 0.36
▸ CCNT1 O60563 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ DYRK3 O43781 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ DYRK2 Q92630 1/20 0.35
▸ DYRK4 Q9NR20 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30347844 0.88 TDO2 (0.55) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25156876 0.88 TDO2 (0.55) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL30348731 0.86 TDO2 (0.55) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25519958 0.86 TDO2 (0.55) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL30348108 0.85 DYRK1A (0.55) DYRK1ACLK3CLK2BRD4GSK3B
SCHEMBL25157223 0.85 DYRK1A (0.55) DYRK1ACLK3CLK2BRD4GSK3B
SCHEMBL25519960 0.85 TDO2 (0.52) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25157140 0.85 TDO2 (0.58) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL30347328 0.85 TDO2 (0.58) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25519964 0.84 TDO2 (0.51) TDO2DYRK1ACLK3CLK2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TDO2 539/4885DYRK1A 1/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback